Compare IVA & VMET Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | IVA | VMET |
|---|---|---|
| Founded | 2011 | 2011 |
| Country | France | Canada |
| Employees | 77 | 8 |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 1.1B |
| IPO Year | N/A | N/A |
| Metric | IVA | VMET |
|---|---|---|
| Price | $5.16 | $12.25 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 10 | 0 |
| Target Price | ★ $16.20 | N/A |
| AVG Volume (30 Days) | ★ 474.4K | 210.9K |
| Earning Date | 03-30-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $185.47 |
| Revenue Next Year | $751.20 | $16.05 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.94 | $9.10 |
| 52 Week High | $7.98 | $13.73 |
| Indicator | IVA | VMET |
|---|---|---|
| Relative Strength Index (RSI) | 39.37 | 54.28 |
| Support Level | $5.04 | $9.39 |
| Resistance Level | $6.42 | $13.73 |
| Average True Range (ATR) | 0.30 | 0.69 |
| MACD | -0.01 | 0.14 |
| Stochastic Oscillator | 24.71 | 50.50 |
Inventiva SA is a France-based biopharmaceutical company specialized in developing drugs that impact on nuclear receptors, transcription factors and epigenetic modulation. The company is focused on developing its product candidate, lanifibranor, for the treatment of patients with non-alcoholic steatohepatitis, or NASH, a disease for which there are currently no approved therapies. The company is also involved in developing a portfolio of pre-clinical therapy programs. It operates in the segment of Service delivery and clinical stage research, notably into therapies in the areas of oncology, fibrosis, and rare diseases. All the company's operations are in France. Majority of the group's revenue is derived from its research partnerships with AbbVie and BI.
Versamet Royalties Corp is a diversified metals royalty and streaming company with exposure to a range of resource royalties and streams including gold, silver, copper, zinc, graphite and uranium, across a variety of jurisdictions. The Company's operating segments are considered to be its individual royalties, streams and the Greenstone gold interest.